acic 400 mg tablett
lex ano uab - atsikloviir - tablett - 400mg 70tk; 400mg 35tk
acic 400 mg tablett
ideal trade links uab - atsikloviir - tablett - 400mg 35tk
aciclovir actavis kreem
teva b.v. - atsikloviir - kreem - 50mg 1g 5g 1tk; 50mg 1g 10g 1tk
acic 5% kreem
sandoz pharmaceuticals d.d. - atsikloviir - kreem - 50mg 1g 2g 1tk
aciclovir actavis tablett
actavis nordic a/s - atsikloviir - tablett - 400mg 10tk
acic 400 mg tablett
globalex pharma oÜ - atsikloviir - tablett - 400mg 35tk; 400mg 70tk
acic-ophtal silmasalv
dr. winzer pharma gmbh - atsikloviir - silmasalv - 30mg 1g 4.5g 1tk
aciclovir-ratiopharm infusioonilahuse pulber
merckle gmbh - atsikloviir - infusioonilahuse pulber - 250mg 5tk
verzenios
eli lilly nederland b.v. - abemaciclib - rinnanäärmed - antineoplastilised ained - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.